Drugs / Prolanta
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02534922 | Feb 2016 → Feb 2019 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Oncolix, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prolanta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02534922 ↗ |
| Action | Inhibit | “create an antagonist of the prolactin receptor” NCT02534922 ↗ |
| Modality | Protein / enzyme biologic | “recombinant analog of the human prolactin protein” NCT02534922 ↗ |
| Route | Subcutaneous | “Daily subcutaneous dosing” NCT02534922 ↗ |